Awithin the 5-Year Follow-Up Period; Bwild Type; Clymph Node Metastasis

Awithin the 5-Year Follow-Up Period; Bwild Type; Clymph Node Metastasis

Supplementary Table 1.Average CCND1 copy numbers in primary melanomas with (N=32) or without (N=23) BRAF or NRAS mutations

Sample no. / metastasis formationa / localization of metastasis / ulceration / BRAFV600 mutation status / NRASQ61 mutation status / CCND1 copy number index
1 / ─ / ─ / ─ / V600E / WTb / 2.0
2 / + / liver / ─ / V600K / WT / 2.3
3 / ─ / ─ / ─ / V600E / WT / 2.1
4 / ─ / ─ / + / V600E / WT / 2.2
5 / + / brain / + / V600E / WT / 2.1
7 / + / LNc, lung, brain / + / V600E / WT / 4.1
9 / + / brain / + / V600K / WT / 3.3
10 / + / LN / + / V600E / WT / 5.3
11 / + / brain / + / V600E / WT / 15.0
12 / ─ / ─ / ─ / V600E / WT / 4.1
13 / + / LN / ─ / V600E / WT / 2.1
15 / ─ / ─ / + / V600E / WT / 3.2
24 / ─ / ─ / ─ / V600R / WT / 3.0
25 / ─ / ─ / ─ / V600E / WT / 1.7
26 / + / LN / + / V600E / WT / 2.1
27 / + / liver / ─ / V600E / WT / 2.4
28 / + / brain, liver / + / V600E / WT / 3.0
29 / + / brain / + / V600E / WT / 2.5
30 / ─ / ─ / + / V600E / WT / 3.5
31 / + / LN / + / V600E / WT / 2.6
32 / + / lung, brain / + / V600E / WT / 6.8
33 / + / liver / + / V600E / WT / 2.2
34 / + / LN, liver / + / V600E / WT / 2.3
35 / ─ / ─ / ─ / V600E / WT / 2.7
6 / + / LN, lung, brain / + / WT / Q61K / 3.3
8 / + / LN, cutan, brain / + / WT / Q61K / 4.4
14 / ─ / ─ / ─ / WT / Q61R / 2.1
36 / + / lung / + / WT / Q61K / 8.2
37 / + / LN / + / WT / Q61K / 2.6
38 / ─ / ─ / ─ / WT / Q61K / 3.5
39 / + / LN / ─ / WT / Q61R / 2.2
40 / + / LN, cutan / ─ / WT / Q61L / 2.5
16 / ─ / ─ / ─ / WT / WT / 1.9
17 / + / LN / + / WT / WT / 1.9
18 / + / LN / + / WT / WT / 2.0
20 / + / LN / + / WT / WT / 4.5
21 / ─ / ─ / ─ / WT / WT / 1.8
22 / + / LN / ─ / WT / WT / 2.8
23 / ─ / ─ / ─ / WT / WT / 5.9
41 / ─ / ─ / ─ / WT / WT / 2.1
42 / ─ / ─ / + / WT / WT / 2.5
43 / ─ / ─ / ─ / WT / WT / 2.6
44 / + / lung, brain / + / WT / WT / 2.0
Sample no. / metastasis formationa / localization of metastasis / ulceration / BRAFV600 mutation status / NRASQ61 mutation status / CCND1 copy number index
45 / ─ / ─ / ─ / WT / WT / 2.4
46 / + / LN / ─ / WT / WT / 2.0
47 / + / LN / ─ / WT / WT / 2.0
48 / ─ / ─ / ─ / WT / WT / 2.4
49 / ─ / ─ / ─ / WT / WT / 3.8
50 / + / cutan, lung / + / WT / WT / 15.0
51 / + / liver / + / WT / WT / 1.5
52 / + / brain / + / WT / WT / 2.3
53 / + / LN, lung / + / WT / WT / 9.1
54 / ─ / ─ / ─ / WT / WT / 1.7
55 / + / LN, liver / + / WT / WT / 5.0
56 / + / lung, liver, bone / + / WT / WT / 1.9

awithin the 5-year follow-up period; bwild type; clymph node metastasis